BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1664 related articles for article (PubMed ID: 27713627)

  • 1. Elevated circulating PAI-1 levels are related to lung function decline, systemic inflammation, and small airway obstruction in chronic obstructive pulmonary disease.
    Wang H; Yang T; Li D; Wu Y; Zhang X; Pang C; Zhang J; Ying B; Wang T; Wen F
    Int J Chron Obstruct Pulmon Dis; 2016; 11():2369-2376. PubMed ID: 27713627
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Plasminogen activator inhibitor-1 is elevated in patients with COPD independent of metabolic and cardiovascular function.
    Waschki B; Watz H; Holz O; Magnussen H; Olejnicka B; Welte T; Rabe KF; Janciauskiene S
    Int J Chron Obstruct Pulmon Dis; 2017; 12():981-987. PubMed ID: 28356730
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Increased levels of inflammatory biomarker CX3CL1 in patients with chronic obstructive pulmonary disease.
    Hao W; Li M; Zhang C; Zhang Y; Du W
    Cytokine; 2020 Feb; 126():154881. PubMed ID: 31629111
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Serum metalloproteinase-9 is related to COPD severity and symptoms - cross-sectional data from a population based cohort-study.
    Linder R; Rönmark E; Pourazar J; Behndig A; Blomberg A; Lindberg A
    Respir Res; 2015 Feb; 16(1):28. PubMed ID: 25849664
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Soluble urokinase-type plasminogen activator receptor is a novel biomarker predicting acute exacerbation in COPD.
    Gumus A; Altintas N; Cinarka H; Kirbas A; Hazıroglu M; Karatas M; Sahin U
    Int J Chron Obstruct Pulmon Dis; 2015; 10():357-65. PubMed ID: 25709430
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Soluble Urokinase-Type Plasminogen Activator Receptor and Arterial Stiffness in Patients with COPD.
    Böcskei RM; Benczúr B; Losonczy G; Illyés M; Cziráki A; Müller V; Bohács A; Bikov A
    Lung; 2019 Apr; 197(2):189-197. PubMed ID: 30820636
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Increased serum TRAIL and DR5 levels correlated with lung function and inflammation in stable COPD patients.
    Wu Y; Shen Y; Zhang J; Wan C; Wang T; Xu D; Yang T; Wen F
    Int J Chron Obstruct Pulmon Dis; 2015; 10():2405-12. PubMed ID: 26609227
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Higher levels of urokinase plasminogen activator system components in the airways of chronic obstructive pulmonary disease patients].
    Xiao W; Tong WL; Ma DD
    Zhonghua Jie He He Hu Xi Za Zhi; 2006 Nov; 29(11):723-6. PubMed ID: 17327049
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Concentration of matrix metalloproteinase-9 in serum of patients with chronic obstructive pulmonary disease and a degree of airway obstruction and disease progression.
    Brajer B; Batura-Gabryel H; Nowicka A; Kuznar-Kaminska B; Szczepanik A
    J Physiol Pharmacol; 2008 Dec; 59 Suppl 6():145-52. PubMed ID: 19218638
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The clinical implication of serum cyclophilin A in patients with chronic obstructive pulmonary disease.
    Zhang M; Tang J; Yin J; Wang X; Feng X; Yang X; Shan H; Zhang Q; Zhang J; Li Y
    Int J Chron Obstruct Pulmon Dis; 2018; 13():357-363. PubMed ID: 29403273
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Circulating syndecan-1 as a novel biomarker relates to lung function, systemic inflammation, and exacerbation in COPD.
    Li D; Wu Y; Guo S; Qin J; Feng M; An Y; Zhang J; Li Y; Xiong S; Zhou H; Zeng Q; Chen L; Wen F
    Int J Chron Obstruct Pulmon Dis; 2019; 14():1933-1941. PubMed ID: 31695352
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The clinical value of suPAR in diagnosis and prediction for patients with chronic obstructive pulmonary disease: a systematic review and meta-analysis.
    Huang Q; Xiong H; Shuai T; Wang Y; Zhang C; Zhang M; Zhu L; Lu J; Liu J
    Ther Adv Respir Dis; 2020; 14():1753466620938546. PubMed ID: 32643535
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pathogenesis of cigarette smoke-induced chronic obstructive pulmonary disease and therapeutic effects of glucocorticoids and N-acetylcysteine in rats.
    Xu L; Cai BQ; Zhu YJ
    Chin Med J (Engl); 2004 Nov; 117(11):1611-9. PubMed ID: 15569474
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Relationship between plasma matrix metalloproteinase levels, pulmonary function, bronchodilator response, and emphysema severity.
    Koo HK; Hong Y; Lim MN; Yim JJ; Kim WJ
    Int J Chron Obstruct Pulmon Dis; 2016; 11():1129-37. PubMed ID: 27313452
    [TBL] [Abstract][Full Text] [Related]  

  • 15. C-reactive protein levels in stable COPD patients: a case-control study.
    Silva DR; Gazzana MB; Knorst MM
    Int J Chron Obstruct Pulmon Dis; 2015; 10():1719-25. PubMed ID: 26357470
    [TBL] [Abstract][Full Text] [Related]  

  • 16. What is the impact of different spirometric criteria on the prevalence of spirometrically defined COPD and its comorbidities? Results from the population-based KORA study.
    Karrasch S; Brüske I; Smith MP; Thorand B; Huth C; Ladwig KH; Kronenberg F; Heinrich J; Holle R; Peters A; Schulz H
    Int J Chron Obstruct Pulmon Dis; 2016; 11():1881-94. PubMed ID: 27574413
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Effects of shuxuening injection on the levels of serum matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 in acute exacerbated chronic obstructive pulmonary disease patients].
    Wang TJ; Xie ZH; Zhao ZZ
    Zhongguo Zhong Xi Yi Jie He Za Zhi; 2012 Feb; 32(2):191-4. PubMed ID: 22574591
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Metalloproteinase-9/tissue inhibitor of metalloproteinase-1 in induced sputum in patients with asthma and chronic obstructive pulmonary disease and their relationship to airway inflammation and airflow limitation].
    Xin XF; Zhao M; Li ZL; Song Y; Shi Y
    Zhonghua Jie He He Hu Xi Za Zhi; 2007 Mar; 30(3):192-6. PubMed ID: 17572998
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Relationship between airway obstruction and C-reactive protein levels in a community-based population of Korea.
    Yoo B; Lee SH; Kim SY; Leem AY; Chung KS; Kim EY; Jung JY; Kang YA; Park MS; Chang J; Kim YS; Park Y
    Int J Tuberc Lung Dis; 2019 Nov; 23(11):1228-1234. PubMed ID: 31718761
    [No Abstract]   [Full Text] [Related]  

  • 20. Serum Endostatin Is a Novel Marker for COPD Associated with Lower Lung Function, Exacerbation and Systemic Inflammation.
    Wu Y; Qin J; He J; Shen Y; Wang H; Li Y; Zeng Q; Dong J; An Y; Xiong S; Feng M; Wen F
    Int J Chron Obstruct Pulmon Dis; 2020; 15():397-407. PubMed ID: 32158205
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 84.